NASDAQ: IBRXImmunitybio Inc Stock
$7.35+2.24 (+43.84%)
Updated Apr 26, 2024
ImmunityBio shares are trading higher... find out Why IBRX Price Moved with a free WallStreetZen account
Why Price MovedIBRX Price
$7.35
Fair Value Price
-$1.26
Market Cap
$4.95B
52 Week Low
$1.25
52 Week High
$7.74
P/E
-6.39x
P/B
-8.44x
P/S
4,105.06x
PEG
N/A
Dividend Yield
N/A
Revenue
$622.00k
Earnings
-$583.20M
Gross Margin
100%
Operating Margin
-72,996.46%
Profit Margin
-93,761.4%
Debt to Equity
-1.86
Operating Cash Flow
-$367M
Beta
1.77
Next Earnings
Jun 12, 2024
Ex-Dividend
N/A
Next Dividend
N/A
IBRX Overview
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how IBRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
IBRX ($7.35) is overvalued by 683.03% relative to our estimate of its Fair Value price of -$1.26 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
IBRX ($7.35) is not significantly undervalued (683.03%) relative to our estimate of its Fair Value price of -$1.26 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
IBRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more IBRX due diligence checks available for Premium users.
Be the first to know about important IBRX news, forecast changes, insider trades & much more!
IBRX News
Valuation
IBRX fair value
Fair Value of IBRX stock based on Discounted Cash Flow (DCF)
Price
$7.35
Fair Value
-$1.26
Undervalued by
683.03%
IBRX ($7.35) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
IBRX ($7.35) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
IBRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
IBRX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6.39x
Industry
14.88x
Market
41.14x
IBRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-8.44x
Industry
5.85x
IBRX's financial health
Profit margin
Revenue
$139.0k
Net Income
-$233.4M
Profit Margin
-167,907.9%
IBRX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
IBRX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$504.5M
Liabilities
$1.1B
Debt to equity
-1.86
IBRX's short-term assets ($294.08M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IBRX's long-term liabilities ($1.03B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IBRX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
IBRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$115.3M
Investing
$2.2M
Financing
$200.5M
IBRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
IBRX vs Biotech Stocks
Immunitybio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.